PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.902
https://www.valueinhealthjournal.com/article/S1098-3015(19)33280-2/fulltext
Title :
PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33280-2&doi=10.1016/j.jval.2019.09.902
First page :
Section Title :
Open access? :
No
Section Order :
10794